First-generation EGFR-TKIs, gefitinib, erlotinib, and icotinib, have shown superior response rates and longer survival compared to chemotherapy in advanced NSCLC, leading to studies on their adjuvant use in resected NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.